Biomerieux

Biomerieux FCF Yield

The Free Cash Flow Yield of Biomerieux (BIM.PA) as of Nov 18, 2026 is 4.14 %. In the previous year, Free Cash Flow Yield was 2.94 % — a change of 40.90% (higher).

FCF Yield

4.14 %

YoY

40.90%

Last updated:

Free Cash Flow Yield of Biomerieux is 2025 4.14 % . Free Cash Flow Yield of Biomerieux was 2024 2.94 % . It decreases by 40.90% higher compared to the previous year.

The Biomerieux FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
1.59 EUR
Jan 1, 2019
1.24 EUR
Jan 1, 2020
2.79 EUR
Jan 1, 2021
4.76 EUR
Jan 1, 2022
1.72 EUR
Jan 1, 2023
0.98 EUR
Jan 1, 2024
2.94 EUR
Jan 1, 2025
4.14 EUR
The Biomerieux FCF Yield history
YEARFCF YieldYoY
4.14 %+40.90%
2.94 %+200.19%
0.98 %-43.15%
1.72 %-63.84%
4.76 %+70.65%
2.79 %+125.48%
1.24 %-21.91%
1.59 %+9.89%
1.44 %+53.80%
0.94 %+0.79%
0.93 %-27.39%
1.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerieux Stock analysis

What does Biomerieux do? Biomerieux SA is a French company that operates in the field of in vitro diagnostics. The company was founded in 1963 by French biologist Alain Merieux and has since continued to grow. Today, Biomerieux employs around 12,000 people in over 150 countries worldwide and is listed on the Paris Stock Exchange. Biomerieux's business model is based on the development, production, and marketing of diagnostic products for various areas of medicine. This includes infectious diseases, cancer, and cardiovascular diseases. The company is divided into two main business segments: Clinical Diagnostics and Industrial Microbiology. Under the Clinical Diagnostics segment, Biomerieux offers a wide range of diagnostic products for infectious diseases, including molecular diagnostics, blood-based tests, and laboratory automation solutions. Some of the most well-known products include the VIDAS immunodiagnostic test, the FilmArray multiplex PCR test, and the VITEK automated system for microorganism identification. Under the Industrial Microbiology segment, Biomerieux is a leading provider of products for the microbiological analysis of food, beverages, and pharmaceutical products. The company offers a wide range of products for microbiological quality control, which help ensure the safety and quality of food and pharmaceutical products. These include the TEMPO system for assessing microorganism growth and the Bactalert blood culture system for rapid detection of bacteria in blood cultures. In addition to its main business segments, Biomerieux also offers specialty products for use in veterinary diagnostics and water analysis. The company works closely with clinical laboratories and health authorities to improve the diagnosis of infectious diseases and combat epidemics. Over the years, Biomerieux has built a strong research and development department focused on developing innovative diagnostic products. The company has also made a number of strategic acquisitions to expand its product portfolio and enter new markets. For example, in 2020, Biomerieux acquired Suzhou Hybiome Biomedical Engineering in China to strengthen its presence in the Chinese market. In summary, Biomerieux is a leading company in the field of in vitro diagnostics. Its wide range of products and global network make it an important partner for laboratories, hospitals, and the food and pharmaceutical industries. With its strong research and development department and strategic acquisitions, Biomerieux will continue to play a crucial role in the fight against infectious diseases and the improvement of patient care. Biomerieux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerieux stock

Free Cash Flow Yield of Biomerieux is 4.14 % in 2025.

Free Cash Flow Yield of Biomerieux changed from 2.94 % to 4.14 %, representing a 40.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Biomerieux since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Biomerieux with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biomerieux

All Key Metrics — Biomerieux